Morgane Mounier1, Nadine Bossard2, Laurent Remontet2, Aurélien Belot3, Pamela Minicozzi4, Roberta De Angelis5, Riccardo Capocaccia5, Jean Iwaz2, Alain Monnereau6, Xavier Troussard7, Milena Sant4, Marc Maynadié8, Roch Giorgi9. 1. Registre des Hémopathies Malignes de Côte d'Or, Université de Bourgogne Franche-Comté, Dijon, France; Université de Lyon, Lyon, France; Université Lyon 1, Villeurbanne, France; Centre national de la recherche scientifique unités mixtes de recherche 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, Villeurbanne, France; Institut national de la santé et de la recherche médicale unités mixtes de recherche S 912 Sciences Economiques et Sociales de la Santé et Traitement de l'Information Médicale, Faculté de Médecine, Marseille, France; Aix Marseille Université unités mixtes de recherche S 912 Institut de recherche pour le développement, Marseille, France. 2. Université de Lyon, Lyon, France; Université Lyon 1, Villeurbanne, France; Centre national de la recherche scientifique unités mixtes de recherche 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, Villeurbanne, France; Service de Biostatistique, Hospices Civils de Lyon, Lyon, France. 3. Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. 4. Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy. 5. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Roma, Italy. 6. Registre des hémopathies malignes de la Gironde, Institut Bergonié, Bordeaux, France; Centre Institut national de la santé et de la recherche médicale U897, Centre d'Investigation Clinique 1401, Bordeaux, France. 7. Registre régional des hémopathies malignes de la Basse Normandie, Centre Hospitalier Universitaire de Caen, Caen, France. 8. Registre des Hémopathies Malignes de Côte d'Or, Université de Bourgogne Franche-Comté, Dijon, France; Service d'Hématologie Biologique, Centre Hospitalier Universitaire de Dijon, Dijon, France. 9. Institut national de la santé et de la recherche médicale unités mixtes de recherche S 912 Sciences Economiques et Sociales de la Santé et Traitement de l'Information Médicale, Faculté de Médecine, Marseille, France; Aix Marseille Université unités mixtes de recherche S 912 Institut de recherche pour le développement, Marseille, France. Electronic address: roch.giorgi@univ-amu.fr.
Abstract
BACKGROUND: Since 2001, the World Health Organization classification of tumours of haematopoietic and lymphoid tissues and the International Classification of Diseases for Oncology (third edition) have improved data collection for lymphoma subtypes in most European cancer registries and allowed reporting on the major non-Hodgkin lymphoma subtypes. Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma. We aimed to compare dynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European areas using data for survival from the largest number of collaborative European population-based cancer registries (EUROCARE). METHODS: We considered follicular lymphoma and diffuse large B-cell lymphoma cases in patients aged older than 15 years diagnosed between Jan 1, 1996, and Dec 31, 2004, and recorded in 43 cancer registries in five areas: Scotland and Wales, and northern, central, eastern, and southern Europe. We excluded cases incidentally diagnosed at autopsy or known from death certificates only. The vital status could be updated on Dec 31, 2008, in all registries but the French ones (Dec 31, 2007). We obtained changes in net survival with the Pohar-Perme estimator and excess mortality rate with a flexible parametric model according to age and year of diagnosis. FINDINGS: We identified 13,988 follicular lymphoma and 25,320 diffuse large B-cell lymphoma cases. We noted improvements in 5-year net survival for all ages between the 1999-2001 and 2002-04 periods for both cancers (except for follicular lymphoma in Scotland and Wales and diffuse large B-cell lymphoma in eastern Europe). For follicular lymphoma, 5-year net survival in northern Europe was 64% (95% CI 58-71) in 1999-2001 versus 75% (69-80) for 2002-04, for Scotland and Wales, it was 71% (66-76) versus 68% (64-72), for central Europe, it was 64% (61-67) versus 72% (70-75), for southern Europe, it was 67% (63-70) versus 73% (70-76), and for eastern Europe, it was 50% (43-57) versus 61% (54-69). For diffuse large B-cell lymphoma, 5-year net survival in northern Europe was 41% (35-49) versus 58% (54-62), in Scotland and Wales, it was 44% (41-48) versus 52% (49-54), in central Europe, it was 46% (44-47) versus 50% (48-51), in southern Europe, it was 44% (42-47) versus 50% (48-52), and in eastern Europe, it was 47% (41-54) versus 46% (43-50). We noted the largest area disparity during the 2002-04 period between eastern and northern Europe. We noted a significant effect of the year of diagnosis on the excess mortality rate for all ages in all areas, except for diffuse large B-cell lymphoma in eastern Europe. The excess mortality rate was not constant during the follow-up period: we noted a high rate early for both lymphomas, except for follicular lymphoma in northern Europe. INTERPRETATION: Although survival for follicular lymphoma and diffuse large B-cell lymphoma is improving, the results from this study should foster the search for more and better means of improvement of access to adequate care than that at present, as there remains variation in survival between European regions. Study of the dynamics of the excess mortality rate seems to be a useful clinical indicator to help the practitioner's choice of optimum management of patients. FUNDING: Compagnia di San Paolo, Fondazione Cariplo Italy, Italian Ministry of Health, European Commission, Registre des Hémopathies Malignes de Côte d'Or, and French Agence Nationale de la Recherche.
BACKGROUND: Since 2001, the World Health Organization classification of tumours of haematopoietic and lymphoid tissues and the International Classification of Diseases for Oncology (third edition) have improved data collection for lymphoma subtypes in most European cancer registries and allowed reporting on the major non-Hodgkin lymphoma subtypes. Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma. We aimed to compare dynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European areas using data for survival from the largest number of collaborative European population-based cancer registries (EUROCARE). METHODS: We considered follicular lymphoma and diffuse large B-cell lymphoma cases in patients aged older than 15 years diagnosed between Jan 1, 1996, and Dec 31, 2004, and recorded in 43 cancer registries in five areas: Scotland and Wales, and northern, central, eastern, and southern Europe. We excluded cases incidentally diagnosed at autopsy or known from death certificates only. The vital status could be updated on Dec 31, 2008, in all registries but the French ones (Dec 31, 2007). We obtained changes in net survival with the Pohar-Perme estimator and excess mortality rate with a flexible parametric model according to age and year of diagnosis. FINDINGS: We identified 13,988 follicular lymphoma and 25,320 diffuse large B-cell lymphoma cases. We noted improvements in 5-year net survival for all ages between the 1999-2001 and 2002-04 periods for both cancers (except for follicular lymphoma in Scotland and Wales and diffuse large B-cell lymphoma in eastern Europe). For follicular lymphoma, 5-year net survival in northern Europe was 64% (95% CI 58-71) in 1999-2001 versus 75% (69-80) for 2002-04, for Scotland and Wales, it was 71% (66-76) versus 68% (64-72), for central Europe, it was 64% (61-67) versus 72% (70-75), for southern Europe, it was 67% (63-70) versus 73% (70-76), and for eastern Europe, it was 50% (43-57) versus 61% (54-69). For diffuse large B-cell lymphoma, 5-year net survival in northern Europe was 41% (35-49) versus 58% (54-62), in Scotland and Wales, it was 44% (41-48) versus 52% (49-54), in central Europe, it was 46% (44-47) versus 50% (48-51), in southern Europe, it was 44% (42-47) versus 50% (48-52), and in eastern Europe, it was 47% (41-54) versus 46% (43-50). We noted the largest area disparity during the 2002-04 period between eastern and northern Europe. We noted a significant effect of the year of diagnosis on the excess mortality rate for all ages in all areas, except for diffuse large B-cell lymphoma in eastern Europe. The excess mortality rate was not constant during the follow-up period: we noted a high rate early for both lymphomas, except for follicular lymphoma in northern Europe. INTERPRETATION: Although survival for follicular lymphoma and diffuse large B-cell lymphoma is improving, the results from this study should foster the search for more and better means of improvement of access to adequate care than that at present, as there remains variation in survival between European regions. Study of the dynamics of the excess mortality rate seems to be a useful clinical indicator to help the practitioner's choice of optimum management of patients. FUNDING: Compagnia di San Paolo, Fondazione Cariplo Italy, Italian Ministry of Health, European Commission, Registre des Hémopathies Malignes de Côte d'Or, and French Agence Nationale de la Recherche.
Authors: Carla Casulo; Melissa C Larson; Julianne J Lunde; Thomas M Habermann; Izidore S Lossos; Yucai Wang; Loretta J Nastoupil; Christopher Strouse; Dai Chihara; Peter Martin; Jonathon B Cohen; Brad S Kahl; W Richard Burack; Jean L Koff; Yong Mun; Anthony Masaquel; Mei Wu; Michael C Wei; Ashwini Shewade; Jia Li; James Cerhan; Christopher R Flowers; Brian K Link; Matthew J Maurer Journal: Lancet Haematol Date: 2022-04 Impact factor: 30.153
Authors: Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace Journal: Qual Life Res Date: 2017-11-10 Impact factor: 4.147
Authors: Yucai Wang; Shouhao Zhou; Xinyue Qi; Fang Yang; Matthew J Maurer; Thomas M Habermann; Thomas E Witzig; Michael L Wang; Grzegorz S Nowakowski Journal: Blood Cancer J Date: 2022-01-05 Impact factor: 9.812